<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Hum Reprod</journal-id>
<journal-id journal-id-type="iso-abbrev">Hum. Reprod</journal-id>
<journal-id journal-id-type="publisher-id">humrep</journal-id>
<journal-title-group>
<journal-title>Human Reproduction (Oxford, England)</journal-title>
</journal-title-group>
<issn pub-type="ppub">0268-1161</issn>
<issn pub-type="epub">1460-2350</issn>
<publisher>
<publisher-name>Oxford University Press</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29618007</article-id>
<article-id pub-id-type="pmc">5925768</article-id>
<article-id pub-id-type="doi">10.1093/humrep/dey066</article-id>
<article-id pub-id-type="publisher-id">dey066</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Article</subject>
<subj-group subj-group-type="category-toc-heading">
<subject>Reproductive Genetics</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Subphenotype meta-analysis of testicular cancer genome-wide association study data suggests a role for RBFOX family genes in cryptorchidism susceptibility</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Yanping</given-names>
</name>
<xref ref-type="aff" rid="dey066af1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gray</surname>
<given-names>Dione R</given-names>
</name>
<xref ref-type="aff" rid="dey066af1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Robbins</surname>
<given-names>Alan K</given-names>
</name>
<xref ref-type="aff" rid="dey066af1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Crowgey</surname>
<given-names>Erin L</given-names>
</name>
<xref ref-type="aff" rid="dey066af1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chanock</surname>
<given-names>Stephen J</given-names>
</name>
<xref ref-type="aff" rid="dey066af2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Greene</surname>
<given-names>Mark H</given-names>
</name>
<xref ref-type="aff" rid="dey066af2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McGlynn</surname>
<given-names>Katherine A</given-names>
</name>
<xref ref-type="aff" rid="dey066af2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nathanson</surname>
<given-names>Katherine</given-names>
</name>
<xref ref-type="aff" rid="dey066af3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Turnbull</surname>
<given-names>Clare</given-names>
</name>
<xref ref-type="aff" rid="dey066af4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Zhaoming</given-names>
</name>
<xref ref-type="aff" rid="dey066af5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Devoto</surname>
<given-names>Marcella</given-names>
</name>
<xref ref-type="aff" rid="dey066af6">6</xref>
<xref ref-type="aff" rid="dey066af7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Barthold</surname>
<given-names>Julia Spencer</given-names>
</name>
<xref ref-type="aff" rid="dey066af1">1</xref>
<xref ref-type="corresp" rid="dey066cor1"></xref>
<!--<email>Julia.Barthold@nemours.org</email>-->
</contrib>
<contrib contrib-type="author">
<collab>Testicular Cancer Consortium</collab>
</contrib>
</contrib-group>
<aff id="dey066af1"><label>1</label>Nemours Biomedical Research/Alfred I. duPont Hospital for Children, Wilmington, DE, USA</aff>
<aff id="dey066af2"><label>2</label>Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Rockville, MD, USA</aff>
<aff id="dey066af3"><label>3</label>Department of Medicine, Division of Translational Medicine and Human Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA</aff>
<aff id="dey066af4"><label>4</label>Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK</aff>
<aff id="dey066af5"><label>5</label>St. Jude Children’s Research Hospital, Department of Computational Biology, Memphis, TN, USA</aff>
<aff id="dey066af6"><label>6</label>Division of Genetics, Children’s Hospital of Philadelphia and Departments of Biostatistics and Epidemiology, and Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA</aff>
<aff id="dey066af7"><label>7</label>Department of Molecular Medicine, Sapienza University, Rome, Italy</aff>
<author-notes>
<corresp id="dey066cor1">Correspondence address. Nemours Biomedical Research/Alfred I. duPont Hospital for Children, Wilmington, DE, USA. E-mail: <email>Julia.Barthold@nemours.org</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>5</month>
<year>2018</year>
</pub-date>
<pub-date iso-8601-date="2018-03-29" pub-type="epub">
<day>29</day>
<month>3</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>5</month>
<year>2019</year>
</pub-date>
<!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>33</volume>
<issue>5</issue>
<fpage>967</fpage>
<lpage>977</lpage>
<history>
<date date-type="received">
<day>10</day>
<month>11</month>
<year>2017</year>
</date>
<date date-type="rev-recd">
<day>09</day>
<month>2</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>09</day>
<month>3</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2018. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com</copyright-statement>
<copyright-year>2018</copyright-year>
<license license-type="oup-standard" xlink:href="https://academic.oup.com/journals/pages/about_us/legal/notices">
<license-p>This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (<ext-link ext-link-type="uri" xlink:href="https://academic.oup.com/journals/pages/about_us/legal/notices">https://academic.oup.com/journals/pages/about_us/legal/notices</ext-link>)</license-p>
</license>
</permissions>
<self-uri xlink:href="dey066.pdf"></self-uri>
<abstract>
<title>Abstract</title>
<sec id="dey066s1">
<title>STUDY QUESTION</title>
<p>Can subphenotype analysis of genome-wide association study (GWAS) data from subjects with testicular germ cell tumor (TGCT) provide insight into cryptorchidism (undescended testis, UDT) susceptibility?</p>
</sec>
<sec id="dey066s2">
<title>SUMMARY ANSWER</title>
<p>Suggestive intragenic GWAS signals common to UDT, TGCT case–case and TGCT case–control analyses occur in genes encoding RBFOX RNA-binding proteins (RBPs) and their neurodevelopmental targets.</p>
</sec>
<sec id="dey066s3">
<title>WHAT IS KNOWN ALREADY</title>
<p>UDT is a strong risk factor for TGCT, but while genetic risk factors for TGCT are well-known, genetic susceptibility to UDT is poorly understood and appears to be more complex.</p>
</sec>
<sec id="dey066s4">
<title>STUDY DESIGN, SIZE, DURATION</title>
<p>We performed a secondary subphenotype analysis of existing GWAS data from the Testicular Cancer Consortium (TECAC) and compared these results with our previously published UDT GWAS data, and with data previously acquired from studies of the fetal rat gubernaculum.</p>
</sec>
<sec id="dey066s5">
<title>PARTICIPANTS/MATERIALS, SETTING, METHODS</title>
<p>Studies from the National Cancer Institute (NCI), United Kingdom (UK) and University of Pennsylvania (Penn) that enrolled white subjects were the source of the TGCT GWAS data. We completed UDT subphenotype case–case (TGCT/UDT vs TGCT/non-UDT) and case–control (TGCT/UDT vs control), collectively referred to as ‘TECAC’ analyses, followed by a meta-analysis comprising 129 TGCT/UDT cases, 1771 TGCT/non-UDT cases, and 3967 unaffected controls. We reanalyzed our UDT GWAS results comprising 844 cases and 2718 controls by mapping suggestive UDT and TECAC signals (defined as <italic>P</italic> &lt; 0.001) to genes using Ingenuity Pathway Analysis (IPA®). We compared associated pathways and enriched gene categories common to all analyses after Benjamini–Hochberg multiple testing correction, and analyzed transcript levels and protein expression using qRT-PCR and rat fetal gubernaculum confocal imaging, respectively.</p>
</sec>
<sec id="dey066s6">
<title>MAIN RESULTS AND THE ROLE OF CHANCE</title>
<p>We found suggestive signals within 19 genes common to all three analyses, including <italic>RBFOX1</italic> and <italic>RBFOX3</italic>, neurodevelopmental paralogs that encode RBPs targeting (U)GCATG-containing transcripts. Ten of the 19 genes participate in neurodevelopment and/or contribute to risk of neurodevelopmental disorders. Experimentally predicted RBFOX gene targets were strongly overrepresented among suggestive intragenic signals for the UDT (117 of 628 (19%), <italic>P</italic> = 3.5 × 10<sup>−24</sup>), TECAC case–case (129 of 711 (18%), <italic>P</italic> = 2.5 × 10<sup>−27</sup>) and TECAC case–control (117 of 679 (17%), <italic>P</italic> = 2 × 10<sup>−21</sup>) analyses, and a majority of the genes common to all three analyses (12 of 19 (63%), <italic>P</italic> = 3 × 10<sup>−9</sup>) are predicted RBFOX targets. <italic>Rbfox1</italic>, <italic>Rbfox2</italic> and their encoded proteins are expressed in the rat fetal gubernaculum. Predicted RBFOX targets are also enriched among transcripts differentially regulated in the fetal gubernaculum during normal development (<italic>P</italic> = 3 × 10<sup>−31</sup>), in response to <italic>in vitro</italic> hormonal stimulation (<italic>P</italic> = 5 × 10<sup>−45</sup>) and in the cryptorchid LE/orl rat (<italic>P</italic> = 2 × 10<sup>−42</sup>).</p>
</sec>
<sec id="dey066s7">
<title>LARGE SCALE DATA</title>
<p>GWAS data included in this study are available in the database of Genotypes and Phenotypes (dbGaP accession numbers phs000986.v1.p1 and phs001349.v1p1).</p>
</sec>
<sec id="dey066s8">
<title>LIMITATIONS, REASONS FOR CAUTION</title>
<p>These GWAS data did not reach genome-wide significance for any individual analysis. UDT appears to have a complex etiology that also includes environmental factors, and such complexity may require much larger sample sizes than are currently available. The current methodology may also introduce bias that favors false discovery of larger genes.</p>
</sec>
<sec id="dey066s9">
<title>WIDER IMPLICATIONS OF THE FINDINGS</title>
<p>Common suggestive intragenic GWAS signals suggest that <italic>RBFOX</italic> paralogs and other neurodevelopmental genes are potential UDT risk candidates, and potential TGCT susceptibility modifiers. Enrichment of predicted RBFOX targets among differentially expressed transcripts in the fetal gubernaculum additionally suggests a role for this RBP family in regulation of testicular descent. As RBFOX proteins regulate alternative splicing of <italic>Calca</italic> to generate calcitonin gene-related peptide, a protein linked to development and function of the gubernaculum, additional studies that address the role of these proteins in UDT are warranted.</p>
</sec>
<sec id="dey066s10">
<title>STUDY FUNDING/COMPETING INTEREST(S)</title>
<p>The <italic>Eunice Kennedy Shriver</italic> National Institute for Child Health and Human Development (R01HD060769); National Center for Research Resources (P20RR20173), National Institute of General Medical Sciences (P20GM103464), Nemours Biomedical Research, the Testicular Cancer Consortium (U01CA164947), the Intramural Research Program of the NCI, a support services contract HHSN26120130003C with IMS, Inc., the Abramson Cancer Center at Penn, National Cancer Institute (CA114478), the Institute of Cancer Research, UK and the Wellcome Trust Case–Control Consortium (WTCCC) 2. None of the authors reports a conflict of interest.</p>
</sec>
</abstract>
<kwd-group>
<kwd>cryptorchidism</kwd>
<kwd>genetic diagnosis</kwd>
<kwd>testicular cancer</kwd>
<kwd>RNA-binding proteins</kwd>
<kwd>risk factors</kwd>
<kwd>genetic predisposition to disease</kwd>
</kwd-group>
<funding-group>
<award-group award-type="grant">
<funding-source>
<named-content content-type="funder-name">National Institute for Child Health and Human Development</named-content>
</funding-source>
<award-id>R01HD060769</award-id>
</award-group>
<award-group award-type="grant">
<funding-source>
<named-content content-type="funder-name">National Center for Research Resources</named-content>
<named-content content-type="funder-identifier">10.13039/100000097</named-content>
</funding-source>
<award-id>P20RR20173</award-id>
</award-group>
<award-group award-type="grant">
<funding-source>
<named-content content-type="funder-name">National Institute of General Medical Sciences</named-content>
<named-content content-type="funder-identifier">10.13039/100000057</named-content>
</funding-source>
<award-id>P20GM103464</award-id>
</award-group>
<award-group award-type="grant">
<funding-source>
<named-content content-type="funder-name">Nemours Biomedical Research</named-content>
</funding-source>
<award-id>U01CA164947</award-id>
</award-group>
<award-group award-type="grant">
<funding-source>
<named-content content-type="funder-name">National Cancer Institute</named-content>
<named-content content-type="funder-identifier">10.13039/100000054</named-content>
</funding-source>
<award-id>HHSN26120130003C</award-id>
</award-group>
<award-group award-type="grant">
<funding-source>
<named-content content-type="funder-name">National Cancer Institute</named-content>
<named-content content-type="funder-identifier">10.13039/100000054</named-content>
</funding-source>
<award-id>CA114478</award-id>
</award-group>
</funding-group>
<counts>
<page-count count="11"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>